Efficacy and Safety of Intra-articular Injections of Frozen Platelet-Rich Plasma in Patients With Knee Osteoarthritis
This trial has no sites in United States.
It has sites in one country. Choose a country to see its sites.
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 40 and 85 years old?
Source: NCT07329361, who can take part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- MiKS Hospital
- Trial code
- NCT07329361
- Record updated
- 9 January 2026
- Original description
Evaluation of intra-articular injections in knee osteoarthritis using frozen-stored PRP. Compared with intra-articular injections of PRP applied at the time of collection.Read full original descriptionShow less
Efficacy and Safety of Intra-articular Injections of Frozen Platelet-Rich Plasma in Patients With Knee Osteoarthritis: Randomized Control Trial
Evaluation of intra-articular injections in knee osteoarthritis using frozen-stored PRP. Compared with intra-articular injections of PRP applied at the time of collection.
Inclusion: Patients of both sexes; Aged between 40 and 85 years old; Diagnosed with osteoarthritis through clinical radiological examination; Joint pain equal to or less than 75 points on the KOOS (pain); Radiological severity grades 1, 2, and 3 according to the Ahlbäck scale; Indication for intra-articular PRP infiltration; Body Mass Index values between 20 and 35; Negative serological tests for syphilis, HIV, HBV, and HCV; Possibility of observation during the follow-up period; Signature of informed consent.
Exclusion: Previous arthroscopy in the last year; Intra-articular corticosteroid or PRP injection in the last 6 months; Diagnosed polyarticular disease; Systemic autoimmune rheumatic disease (connective tissue diseases and systemic necrotizing vasculitis); Anemia or other hematological disorders; Positive serological tests for SYPHILIS, HIV, HBV, and HCV; Poorly controlled diabetes mellitus; Patients allergic to paracetamol; Body mass index >35; Severe mechanical deformity; Intra-articular hyaluronic acid injection in the last 12 months; Undergoing immunosuppressive treatments; Pregnancy or breastfeeding.